Literature DB >> 24927265

The clinical management of chronic myelomonocytic leukemia.

Eric Padron1, Rami Komrokji1, Alan F List1.   

Abstract

Chronic myelomonocytic leukemia (CMML) is an aggressive malignancy characterized by peripheral monocytosis and ineffective hematopoiesis. It has been historically classified as a subtype of the myelodysplastic syndromes (MDSs) but was recently demonstrated to be a distinct entity with a distinct natural history. Nonetheless, clinical practice guidelines for CMML have been inferred from studies designed for MDSs. It is imperative that clinicians understand which elements of MDS clinical practice are translatable to CMML, including which evidence has been generated from CMML-specific studies and which has not. This allows for an evidence-based approach to the treatment of CMML and identifies knowledge gaps in need of further study in a disease-specific manner. This review discusses the diagnosis, prognosis, and treatment of CMML, with the task of divorcing aspects of MDS practice that have not been demonstrated to be applicable to CMML and merging those that have been shown to be clinically similar.

Entities:  

Mesh:

Year:  2014        PMID: 24927265

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN: 1543-0790


  8 in total

Review 1.  Chronic myelomonocytic leukemia prognostic classification and management: evidence base and current practice.

Authors:  Dorothée Selimoglu-Buet; Eric Solary
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

2.  Chronic myelomonocytic leukemia with double-mutations in DNMT3A and FLT3-ITD treated with decitabine and sorafenib.

Authors:  Jia Gu; Zhiqiong Wang; Min Xiao; Xia Mao; Li Zhu; Ying Wang; Wei Huang
Journal:  Cancer Biol Ther       Date:  2017-01-19       Impact factor: 4.742

3.  A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML).

Authors:  Eric Padron; Amy Dezern; Marcio Andrade-Campos; Kris Vaddi; Peggy Scherle; Qing Zhang; Yan Ma; Maria E Balasis; Sara Tinsley; Hanadi Ramadan; Cassandra Zimmerman; David P Steensma; Gail J Roboz; Jeffrey E Lancet; Alan F List; Mikkael A Sekeres; Rami S Komrokji
Journal:  Clin Cancer Res       Date:  2016-02-08       Impact factor: 12.531

Review 4.  Chronic Myelomonocytic Leukemia: 2018 Update to Prognosis and Treatment.

Authors:  Hany Elmariah; Amy E DeZern
Journal:  Curr Hematol Malig Rep       Date:  2019-06       Impact factor: 3.952

Review 5.  Dual effect of oxidative stress on leukemia cancer induction and treatment.

Authors:  Udensi K Udensi; Paul B Tchounwou
Journal:  J Exp Clin Cancer Res       Date:  2014-12-18

Review 6.  Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions.

Authors:  Peter Valent; Attilio Orazi; Michael R Savona; Mrinal M Patnaik; Francesco Onida; Arjan A van de Loosdrecht; Detlef Haase; Torsten Haferlach; Chiara Elena; Lisa Pleyer; Wolfgang Kern; Tea Pemovska; Gregory I Vladimer; Julie Schanz; Alexandra Keller; Michael Lübbert; Thomas Lion; Karl Sotlar; Andreas Reiter; Theo De Witte; Michael Pfeilstöcker; Klaus Geissler; Eric Padron; Michael Deininger; Alberto Orfao; Hans-Peter Horny; Peter L Greenberg; Daniel A Arber; Luca Malcovati; John M Bennett
Journal:  Haematologica       Date:  2019-05-02       Impact factor: 9.941

7.  Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia.

Authors:  Anthony M Hunter; Hannah Newman; Amy E Dezern; David P Steensma; Sandrine Niyongere; Gail J Roboz; Qianxing Mo; Onyee Chan; Aaron Gerds; David A Sallman; William Dominguez-Viqueira; Christopher Letson; Maria E Balasis; Markus Ball; Traci Kruer; Hailing Zhang; Jeffrey E Lancet; Alan F List; Mikkael A Sekeres; Rami S Komrokji; Eric Padron
Journal:  Clin Cancer Res       Date:  2021-07-12       Impact factor: 12.531

8.  An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies.

Authors:  E Padron; G Garcia-Manero; M M Patnaik; R Itzykson; T Lasho; A Nazha; R K Rampal; M E Sanchez; E Jabbour; N H Al Ali; Z Thompson; S Colla; P Fenaux; H M Kantarjian; S Killick; M A Sekeres; A F List; F Onida; R S Komrokji; A Tefferi; E Solary
Journal:  Blood Cancer J       Date:  2015-07-31       Impact factor: 11.037

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.